Solid-phase synthesis of nucleoside analogues

Journal of Combinatorial Chemistry

Volumn 5, Issue 3, 2003, Pages 292-310

  Epple, Robert ^a   Kudirka, Romas ^a   Greenberg, William A ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' ACETAL; ACETAL DERIVATIVE; CHEMICAL COMPOUND; NUCLEOSIDE; PURINE NUCLEOSIDE; PYRIMIDINE NUCLEOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; PUBLICATION; SOLID; SYNTHESIS;

COMBINATORIAL CHEMISTRY TECHNIQUES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; NUCLEOSIDES;

EID: 0141786954     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc020087f     Document Type: Article

References (86)

1. Suhadolnik, R. J. Nucleosides as Biological Probes; Wiley: New York, 1979.
2. (a) Huryn, D. M.; Okabe, M. Chem. Rev. 1992, 92, 1745-1768.
3. (b) Tan, X.; Chu, C. K.; Boudinot, F. D. Adv. Drug Deliv. Rev. 1999, 39, 117-151.
4. (c) Mansour, T. S.; Storer, R. Curr. Pharm. Des. 1997, 3, 227-264.
5. (a) Plunkett, W.; Saunders, P. P. Pharmacol. Ther. 1991, 49, 239-268.
6. (b) Cheson, B. D.; Keating, M. J.; William Plunkett, W. Nucleoside Analogues in Cancer Therapy; Marcel Dekker: New York, 1997; Vol. 12.
7. (c) Shuter, J. Cancer Invest. 1999, 17, 145-152.
8. (d) Kolesar, J. M.; Morris, A. K.; Kuhn, J. G. J. Oncol. Pharm. Pract. 1996, 2, 211-224.
9. (e) Robins, R. K.; Revankar, G. R. Med. Res. Rev. 1985, 5, 273-296.
10. (a) Knapp, S. Chem. Rev. 1995, 95, 1859-1876.
11. (b) Isono, K. Pharmacol. Ther. 1991, 52, 269-286. Isono, K J. Antibiotics 1988, 41, 1711-1739.
12. (b) Isono, K. Pharmacol. Ther. 1991, 52, 269-286. Isono, K J. Antibiotics 1988, 41, 1711-1739.
13. (a) Ralevic, V.; Burnstock, G. Pharmacol. Rev. 1998, 50, 413-492.
14. (b) Klinger, M.; Freissmuth, M.; Nanoff, C. Cell. Signaling 2002, 14, 99-108.
15. (c) Williams, M.; Jarvis, M. F. Biochem. Pharmacol. 2000, 59, 1173-1185.
16. (d) Kaiser, S. M.; Quinn, R. J. Drug Discovery Today 1999, 4, 542-551.
17. (e) Poulsen, S.-A.; Quinn, R. J. Bioorg. Med. Chem. 1998, 6, 619-641.
18. (f) Palmer, T. M.; Stiles, G. L. Neuropharmacology 1995, 34, 683-694.
19. (g) Moreau, J.-L.; Huber, G. Brain Res. Rev. 1999, 31, 65-82.
20. (h) Daval, J.-L.; Nicolas, F.; Doriat, J.-F. Pharmacol. Ther. 1996, 71, 325-335.
21. (i) Feoktistov, I.; Biaggioni, I. Pharmacol. Rev. 1997, 49, 381-402.
22. (j) Von Lubitz, D. K. J. E. Eur. J. Pharmacol. 1999, 365, 9-25.
23. (k) Sawynok, J. Eur. J. Pharmacol. 1998, 317, 1-11.
24. (l) Mubagwa, K.; Flameng, W. Cardiovasc. Res. 2001, 52, 25-39.
25. (m) Tabrizchi, R.; Bedi, S. Pharmacol. Ther. 2001, 91, 133-147.
26. (n) Henning, R. H. Pharmacol. Ther. 1997, 74, 115-128.
27. (o) de Jong, J. W.; de Jonge, R.; Keijzer, E.; Bradamante, S. Pharmacol. Ther. 2000, 87, 141-149.
28. (p) Olah, M. E.; Stiles, G. L. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 581-606.
29. (q) Erion, M. D. Annu. Rep. Med. Chem. 1993, 28, 295-304.
30. Roth, V. R.; Jarvis, W. R. Emerging Ther. Targets 1999, 3, 73.
31. Klener, P. Basic Clin. Oncol. 1999, 19, 279-295. Kaul, R. Dtsch. Apoth. Ztg. 1995, 135, 19-31.
32. Klener, P. Basic Clin. Oncol. 1999, 19, 279-295. Kaul, R. Dtsch. Apoth. Ztg. 1995, 135, 19-31.
33. (a) Daly, J. W. J. Med. Chem. 1982, 25, 197.
34. (b) Jacobson, K. A.; van Galen, P. J. M.; Williams, M. J. Med. Chem. 1992, 35, 407-422.
35. (c) Jacobsen, K. A.; Kim, H. O.; Siddiqi, S. M.; Olah, M. E.; Stiles, G. L.; von Lubitz, D. K. J. E. Drugs Future 1995, 20, 689-699.
36. (d) DeNinno, M. P. Annu. Rep. Med. Chem. 1998, 33, 111-120.
37. (e) Cristalli, G.; Camaioni, E.; Costanzi, S.; Vittori, S.; Volpini, R.; Klotz, K.-N. Drug Dev. Res. 1998, 45, 176-181.
38. (f) Knutsen, L. J. S.; Sheardown, M. J.; Roberts, S. M.; Mogensen, J. P. ; Olsen, U. B.; Thomsen, C.; Bowler, A. N. Drug Dev. Res. 1998, 45, 214-221.
39. (g) Mueller, C. E. Curr. Med. Chem. 2000, 7, 1269-1288.
40. (h) Mueller, C. E. Farmaco 2001, 56, 77-80.
41. (a) Thompson, L. A.; Ellman, J. A. Chem. Rev. 1996, 96, 555-600.
42. (b) Balkenhohl, F.; von dem Bussche-Huennefeld, C.; Lansky, A.; Zechel, C. Angew. Chem., Int. Ed. Engl. 1996, 35, 2288-2337.
43. (c) Ellman, J. A. Acc. Chem. Res. 1996, 29 (3), 132-143.
44. (d) Nefzi, A.; Ostrech, J. M.; Houghten, R. A. Chem. Rev. 1997, 97, 449-472.
45. (e) Franzen, R. G. J. Comb. Chem. 2000, 2, 195-214.
46. (a) Ghosh, P. K.; Kumar, P.; Gupta, K. C. J. Ind. Chem. Soc. 2000, 77, 109-132.
47. (b) Wada, T.; Sato, Y.; Honda, F.; Kawahara, S.; Sekine, M. J. Am. Chem. Soc. 1997, 119, 12710-12721.
48. (c) Beaucage, S. L.; Iyer, R. P. Tetrahedron 1992, 48, 2223-2311.
49. (a) de Champdore, M.; De Napoli, L.; Di Fabio, G.; Messere, A.; Montesarchio, D.; Piccialli, G. Chem. Commun. 2001, 24, 2598-2599.
50. (b) Bozzoli, A.; Kazmierski, W.; Kennedy, G.; Pasquarello, A.; Pecunioso, A. Bioorg. Med. Chem. Lett. 2000, 10, 2759-2763.
51. (c) Crimmins, M. T.; Zuercher, W. J. Org. Lett. 2000, 2, 1065-106.
52. (d) Khan, S. I.; Grinstaff, M. W. Tetrahedron Lett. 1998, 39, 8031-8034.
53. Sano, S.; Tokunaga, R.; Kun, K. A. Biochim. Biophys. Acta 1971, 244, 201-205.
54. (a) Pedroso, E. Tetrahedron Lett. 1993, 34, 2195.
55. (b) Bozzoli, A.; Kazmierski, W.; Kennedy, G.; Pasquarello, A.; Pecunioso, A. Bioorg. Med. Chem. Lett. 2000, 10, 2759-2763.
56. For a recent example, see: Nicolaou, K. C.; Pfefferkorn, J. A.; Mitchell, H. J.; Roecker, A. J.; Barluenga, S.; Cao, G.-Q.; Affleck, R. L.; Lillig, J. E. J. Am. Chem. Soc. 2000, 122, 9954-9967. For information about the IRORI nanokan system, please visit their website at www.discoverypartners.com/Products/index.html.
57. Merrifield, R. B.; Mitchell, A. R.; Kent, S. B. H.; Enggelhard, M. J. Org. Chem. 1978, 43, 2845.
58. (b) Backes, B. J. Ph.D. Dissertation, UC Berkeley, 1993.
59. Novabiochem Catalog and Peptide Synthesis Handbook 1997/1998, method 16; MilliGen Technical Note 3.10.
60. Novabiochem Catalog and Peptide Synthesis Handbook 1997/1998, method 16; MilliGen Technical Note 3.10.
61. Ueda, T. In Chemistry of Nucleosides and Nucleotides; Townsend, L. B., Ed.; Plenum: New York, 1988; Vol. 1, pp 41-46.
62. Divakar, K. J.; Reese, C. B. J. Chem. Soc., Perkin Trans. 1 1982, 1171-1176.
63. Guibe, F. Tetrahedron 1998, 54, 2967-3041.
64. Mitsunobu, O. Synthesis 1981, 1-28.
65. Endo, T.; Zemlicka, J. J. Org. Chem. 1988, 53, 1887-1894.
66. Padwa, A. 1,3-Dipolar Cycloaddition Chemistry; John Wiley: New York, 1984.
67. Maiti, S. N.; Singh, M. P.; Micetich, R. G. Tetrahedron Lett. 1986, 27, 1423-1424.
68. (a) Greenhill, J. V.; Lue, P. Prog. Med. Chem. 1993, 30, 203-326.
69. (b) Peterlin-Masic, L.; Kikelj, D. Tetrahedron 2001, 57, 7073-7105.
70. (a) Kilburn, J. P.; Lau, J.; Jones, R. C. F. Tetrahedron 2002, 58, 1739-1743.
71. (b) Ghosh, A. K.; Hol, W. G. J.; Fan, E. J. Org. Chem. 2001, 66, 2161-2164.
72. (c) Chen, J.; Pattarawarapan, M.; Zhang, A. J.; Burgess, K. J. Comb. Chem. 2000, 2, 276-281.
73. (d) Dodd, D. S.; Wallace, O. B. Tetrahedron Lett. 1998, 39, 5701-5704.
74. (e) Drewry, D. H.; Gerritz, S. W.; Linn, J. A. Tetrahedron Lett. 1997, 38, 3377-3380.
75. Hydrolysis of the 5′-phosphinamine on the pyrimidine scaffold under basic conditions did not result in the formation of the free 5′-amine 39 and was inert toward any acylation reagents. Instead, it was suggested that the procedure exclusively yields the product of Michael attack of the free amine on the pyrimidine ring (see ref 13b).
76. Roush, W. R.; Lin, X.-F. J. Am. Chem. Soc. 1995, 117, 2236.
77. Ceulemans, G.; Vandendriessche, F.; Rozenski, J.; Herdewijn, P. Nucleosides Nucleotides 1995, 14, 117-128.
78. Robins, M. J.; Doboszewski, B.; Nillson, B. L.; Peterson, M. A. Nucleosides Nucleotides 2000, 19, 69-86.
79. Dess, D.; Martin, J. J. Org. Chem. 1983, 48, 4155-4156.
80. Bunin, B. A. The Combinatorial Index; Academic Press: San Diego, 1998; pp 130-133.
81. Beebe, X.; Schore, N. E.; Kurth, M. J. J. Am. Chem. Soc. 1992, 114, 10061-10062.
82. Nicolaou, K. C.; Winssinger, N.; Vourloumis, D.; Ohshima, T.; Kim, S.; Pfefferkorn, J.; Xu, J.-Y.; Li, T. J. Am. Chem. Soc. 1998, 120, 10814-10826.
83. Epp, J. B.; Widlanski, T. S. J. Org. Chem. 1999, 64, 293-295.
84. Pochet, S.; Kansal, V.; Destouesse, F.; Sarfati, S. R. Tetrahedron Lett. 1990, 31, 6021-6024.
85. Because of the incompatibility of the IRORI cleavap system with our cleavage conditions and the high amount of extractables we observed when using the IRORI cleavap system, we decided to cleave the nucleoside library in-house at GNF. By developing angled plate holders for the Savant centrifuge, we were able to use the advantages of IRORI cleavage plates without using the IRORI cleavap system.
86. Bunin, B. A. The Combinatorial Index; Academic Press: San Diego, 1998; Section 5 and references therein.